AG
RAPT

Algert Global’s RAPT Therapeutics RAPT Stock Holding History

Algert Global’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,935
Closed -$75K – 1305
2024
Q4 		$75K Hold
5,935
– – ﹤0.01% 1134
2024
Q3 		$95K Hold
5,935
– – ﹤0.01% 1119
2024
Q2 		$145K Sell
5,935
-801
-12% -$37K ﹤0.01% 1334
2024
Q1 		$484K Buy
6,736
+2,345
+53% +$326K 0.02% 768
2023
Q4 		$873K Sell
4,391
-3,358
-43% -$416K 0.04% 655
2023
Q3 		$1.03M Sell
7,749
-1,681
-18% -$274K 0.05% 564
2023
Q2 		$1.41M Buy
9,430
+186
+2% +$29K 0.06% 524
2023
Q1 		$1.36M Buy
9,244
+662
+8% +$134K 0.06% 506
2022
Q4 		$1.36M Buy
8,582
+6,872
+402% +$1.1M 0.08% 441
2022
Q3 		$329K Buy
1,710
+264
+18% +$49.9K 0.02% 929
2022
Q2 		$211K Buy
+1,446
New +$193K 0.02% 1011
2021
Q4 		– Sell
-1,395
Closed -$346K – 1086
2021
Q3 		$346K Buy
1,395
+295
+27% +$78K 0.05% 702
2021
Q2 		$280K Sell
1,100
-929
-46% -$174K 0.09% 302
2021
Q1 		$360K Buy
+2,029
New +$335K 0.12% 264

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Algert Global's RAPT Position: Q1 2025 in Review

Algert Global sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 5,935 shares — an estimated $75K sold.

Algert Global first reported a position in RAPT in Q1 2021 and held it in 14 quarters. The position peaked at $1.41M in Q2 2023. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Algert Global reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Algert Global sold 5,935 RAPT Therapeutics shares in Q1 2025, an estimated $75K.
  • Algert Global first reported a position in RAPT Therapeutics in Q1 2021 and held it in 14 quarters.
  • Algert Global's RAPT Therapeutics position peaked at $1.41M in Q2 2023.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.